News

Yahoo Finance14d
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
Nature2y
T cells without limitation
New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer. Has some of the early excitement in the cell ...
Yahoo Finance4d
TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
EDINBURGH, Scotland, April 9, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic ...
pharmaphorum3d
Takeda buys GammaDelta to boost cancer cell therapy credentials
The Abingworth-backed biotech is developing therapies based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role in a host of immune responses and ...
TMCnet13d
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...